Related Videos
Video
Study of SACI-IO for Triple Negative Metastatic Breast Cancer
Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative ...
Video
Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer
Why test the combination of Trodelvy and pembrolizumab?